A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis

Trial Profile

A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis

Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2015

At a glance

  • Drugs Birch pollen allergy immunotherapy HAL Allergy (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus Adverse reactions
  • Sponsors HAL Allergy
  • Most Recent Events

    • 10 Mar 2015 According to HAL Allergy media release, based on the positive outcome of this study, a new accelerated up-dosing regimen for all registered PURETHAL Pollen products has been approved in Germany.
    • 10 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top